Drugs / Opium Tincture USP Deodorized
Opium Tincture USP Deodorized
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02242656 | Dec 2014 → Dec 2017 | BD syndrome, short bowel syndrome | Marathon Pharmaceuticals, LLC | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Opium Tincture USP Deodorized | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02242656 ↗ |
| Known as | MP-101 | “Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops” NCT02242656 ↗ |
| Known as | SR-1C5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL273386 ↗ |
| Modality | Small molecule | — CHEMBL273386 ↗ |
| Route | Oral | “QID oral drops” NCT02242656 ↗ |